morn pre-announc ultomiri revenue ahead consensu
driven strong convers germani
japan guidanc total revenue growth impli revenu also
ahead consensu meanwhil pipelin updat posit compani
continu double-digit revenu growth top larg cap pick
morn alexion pre-announc ultomiri revenu pnh ahu
ahead consensu beat driven ex-
 geographi ultomiri launch track ahead launch
germani patient convert ultomiri sinc drug enter market
juli place launch ahead patient convert
ultomiri despit fact ultomiri seven month head start alexion
previous note speed launch partli attribut concentr
prescrib base germani
though ultomiri enter market japan end launch also
appear track ahead launch time point patient
convert januari
ultomiri also launch austria denmark finland launch addit
european countri anticip beyond though market repres
rel small percentag soliris/ultomiri sale alexion note convers
rate similarli rapid denmark convers rate faster
seen germani
though alexion break soliri sale gmg nmosd specif alexion
disclos neurolog patient soliri decemb impli
rate patient start treatment increas
level alexion previous highlight quarter strongest
growth yet gmg estim patient dynam result revenu
soliri gmg nmosd q/q ahead prior thu
two year neurolog franchis grown largest alexion franchis
patient volum alexion aim increas number neurolog patient one
therapi factor four
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand trend
soliri remain solid launch gmg set eclips launch pnh ahu
expect fear competit soliri wane franchis transfer
ultomiri follow januari launch strensiq wit strong launch
appear destin blockbust statu asset plu minor contribut
kanuma allow compani post industry-lead financi view alexion
premier orphan diseas compani think favor financi outlook increas
confid growth durabl complement franchis posit share
re-rat alexion one larg cap biotech solid growth
prospect consid top larg cap pick maintain price target
data pk-base ph subq
sad/mad data gmg
approv high concentr ultomiri
shorter infus time
drive franchis sale
strensiq kanuma lal-d
achiev
rest pipelin creat
franchis grow faster
project achiev revenue
soliri ultomiri sale fall short
commerci regulatori setback
strensiq ultomiri
dilut acquisit
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu gmg next-gen
ultomiri approv pnh ahu octob pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ
ahu market could compar size pnh market sever refractori
gener myasthenia gravi gmg patient think gmg potenti new
oppi beyond soliri strensiq kanuma achiev commerci success
respect peak sale
alexion disclos total revenu grew y/i impli revenu
approxim q/q y/i ahead consensu
adjust model reflect morn disclosur ep estim
increas
high concentr formul ultomiri reduc infus time
minut expect launch year alexion pipelin includ once-weekli
subq formul ultomiri phase data anticip devic
expect launch pnh ahu bridg trial nmosd gmg could
lead ultomiri iv/subq launch indic alexion also creat
subq formul fcrn move forward gmg sad/mad trial
ph ii begin waiha ph ii compani
second fcrn also enter sad/mad studi may provid
alexion expand clinic plan ultomiri includ investig treatment
complement-medi thrombot microangiopathi cm-tma addit al ppm
hsct-tma disclos previous soliri previous shown efficaci cm-tma
estim effect patient phase trial plan addit alexion
announc initi clinic develop plan next-gener asset
long-act subq formul develop collabor halozym renal basket
studi set enter phase i/ii develop complement-medi renal diseas
final enrol set complet quarter phase focu trial
wilson diseas top-lin result expect
encourag morn disclosur suggest strong perform
alexion key franchis think result highlight opportun
growth remain front provid reason optim
franchis defens investor appreci despit market
neurolog indic two year figur suggest soliri best quarter
growth indic yet increas confid size opportun
franchis neurolog indic driver healthi
growth next sever year ultomiri also continu impress germani
japan strong patient physician interest ultomiri lead rapid
convers upsid revenu estim think bode well ultomiri
launch across futur geographi indic suggest unlik
patient want switch back biosimilar avail continu believ
base ultomiri improv potenc conveni well somewhat
lower annual price rais bar competit franchis moreov
alexion pipelin appear like solidifi compani preemin
complement space think complement franchis suscept
competit market current assum moreov done admir job
rebuild pipelin end sever program pivot
develop key event approach
progress grow revenu transfer franchis ultomiri
rebuild pipelin reward thu far investor pessimist
prospect trade forward pe ratio hope
continu execut posit share re-rat investor better appreci
durabl complement franchis potenti opportun rebuilt
pipelin top larg cap idea maintain price target
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi
gmg soliri becom one success ultra-orphan drug
sale y/i soliri label expand includ
neuromyel optica nmo end june next-gener complement
inhibitor ultomiri seek advanc upon soliriss profil offer greater
conveni potenc phase studi use dose paradigm
demonstr non-inferior soliri trend superior fda approv
pnh grant end decemb alexion plan convert
least pnh market ultomiri fda approv ahu
grant octob alexion expect convert least
 market ultomiri within two year launch subq formul employ
dose on-going initi data anticip alexion
also studi subq co-administ halozym
call could extend dose interv given
steadi new patient add ultomiri abil protect franchis
competit estim sale alexion complement franchis
includ pnh ahu gmg alexion market two
addit ultra-orphan drug strensiq asfotas alfa hypophosphatasia
sever bone diseas approv europ japan gener
sale believ drug potenti
kanuma enzym replac therapi lal defici unfortun
alexion face challeng identifi lal-d patient peak sale like
modest model sale recent alexion acquir
number earli stage asset build pipelin alexion acquir wilson
therapeut april gain access treatment
wilson diseas current phase develop addit alexion
obtain acquisit syntimmun alexion aim
advanc pivot develop warm autoimmun hemolyt
anemia waiha view alexion premier orphan diseas compani
think favor financi outlook increas confid compani
abil convert patient ultomiri posit share re-rat investor
gain confid growth durabl complement franchis
alexion one larg cap biotech solid growth prospect
consid top larg cap pick maintain price target
decis ipr challeng soliri ip
initi phase studi ultomiri iv al
data pk-base registr phase bridg studi weekli subq
initi phase ultomiri iv hsct-tma
launch formul reduc infus time minut
initi phase trial ultomiri cm-tma
launch pnh addit eu geographi
potenti approv launch ultomiri subq pnh ahu
potenti approv launch ultomiri subq gmg nmosd
complet phase enrol wilson diseas
potenti top-lin result wilson diseas
initi phase ii/iii trial waiha
initi phase trial subq formul healthi volunt
initi phase ii trial subq formul gmg
complet acquisit achillion
initi pivot phase combin trial danicopan ultomiri pnh
initi sad/mad trial bival antibody-mimet target fcrn
initi proof-of-concept ph ii kda bi-specif mini-bodi
cowen compani
cowen compani
pnh ahu gmg nmosd cowen
cowen compani
franchis y/i y/i y/i y/i y/i growthstrensiq sale y/i y/i y/i gross total product oper oper oper incom non- tax incom loss net incom y/i base compens incom includ stock includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
franchis sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg compens conting gain loss forward asset liabilitiesaccount expens payable/accru revenuetot use oper invest activitieschang market securitiespay acquisitionspurchas invest financ activitiesdebt issuanc cost excess tax benefit stock option payment mortagag note loan stock salenet proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv franchis soliri ultomiri
risk expect soliri ultomiri includ impact brand biosimilar
competit market share net price advers regulatori decis new market
less-than-expect sale establish market alexion share could also wit
meaning downsid pipelin program fail
